Pfenex Inc. (PFNX) and Reata Pharmaceuticals Inc. (NASDAQ:RETA) Contrasting side by side

Pfenex Inc. (NYSEAMERICAN:PFNX) and Reata Pharmaceuticals Inc. (NASDAQ:RETA) compete with each other in the Biotechnology sector. We will analyze and contrast their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pfenex Inc. 29.41M 5.29 27.28M -0.99 0.00
Reata Pharmaceuticals Inc. 52.35M 53.94 80.55M -2.64 0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Pfenex Inc. and Reata Pharmaceuticals Inc.

Profitability

Table 2 represents Pfenex Inc. (NYSEAMERICAN:PFNX) and Reata Pharmaceuticals Inc. (NASDAQ:RETA)’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Pfenex Inc. -92.76% -43.7% -32.3%
Reata Pharmaceuticals Inc. -153.87% 0% 0%

Liquidity

Pfenex Inc. has a Current Ratio of 3.7 and a Quick Ratio of 3.7. Competitively, Reata Pharmaceuticals Inc.’s Current Ratio is 6.1 and has 6.1 Quick Ratio. Reata Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Pfenex Inc.

Insider and Institutional Ownership

Roughly 81.6% of Pfenex Inc. shares are held by institutional investors while 68.6% of Reata Pharmaceuticals Inc. are owned by institutional investors. 0.1% are Pfenex Inc.’s share held by insiders. Insiders Competitively, held 4.1% of Reata Pharmaceuticals Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Pfenex Inc. 14.08% 19.29% 17.79% -11.15% 22.72% 47.34%
Reata Pharmaceuticals Inc. 13.58% 27.6% 57.18% 19.28% 331.86% 81.44%

For the past year Pfenex Inc.’s stock price has smaller growth than Reata Pharmaceuticals Inc.

Summary

Reata Pharmaceuticals Inc. beats on 6 of the 10 factors Pfenex Inc.

Pfenex Inc., a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. Its lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; PF582, a biosimilar to Lucentis (ranibizumab) for the treatment of patients with retinal diseases; and Px563L, a novel anthrax vaccine candidate in Phase 1a trial. The company also engages in developing a pipeline of additional biosimilar candidates, including PF529, a biosimilar candidate to Neulasta; PF688, a biosimilar candidate to Cimzia; PF530, a biosimilar candidate to Betaseron; PF690, a biosimilar candidate to the reference product Oncaspar; PF444-human growth hormone, a biosimilar candidate to Genotropin; and PF688-certolizumab-pegol, a biosimilar candidate to Cimzia. It has collaboration agreements with Hospira, Inc. and Jazz Pharmaceuticals Ireland Limited. Pfenex Inc. is headquartered in San Diego, California.

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates for patients with rare and life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. Its lead product candidates include Bardoxolone methyl, which is in Phase III clinical trial for the treatment of pulmonary arterial hypertension and associated with connective tissue disease, as well as in Phase II clinical trial for the treatment of pulmonary hypertension due to interstitial lung disease and pulmonary arterial hypertension; and Omaveloxolone that is in Phase II clinical trial for the treatment of FriedreichÂ’s ataxia, mitochondrial myopathies, and metastatic melanoma. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas.